Fitzpatrick Commences Legal Action on Behalf of Client AstraZeneca Over Seroquel Patent

November 14, 2005

For Immediate Release

Contact:
Linda Lee Ficano
Fitzpatrick, Cella
212-218-2284
lficano@fchs.com

Rosemarie Yu / Annette Blum
Edelman
(212) 704-4549 / 642-7781
Rosemarie.Yu@edelman.com
Annette.Blum@edelman.com

New York, NY, November 14, 2005 – Fitzpatrick, Cella, Harper & Scinto announced that it has filed a lawsuit on behalf of AstraZeneca against Teva Pharmaceuticals over its submission of an abbreviated new drug application (ANDA) to the FDA for Seroquel (Active Ingredient Name: quetiapine fumarate). The patent infringement action was filed in the U.S. District Court of New Jersey. The complaint maintains AstraZeneca’s Seroquel patent is valid until its expiration date in September 2011.

Seroquel is of a class of drugs known as atypical antipsychotics, and is one of AstraZeneca’s best selling drugs, generating sales of $1.5 billion last year alone. Attorneys for AstraZeneca are Fitzpatrick, Cella partners Robert L. Baechtold, Pasquale A. Razzano and Steven C. Kline.